via Massachusetts General Hospital
Key Takeaways
- Parathyroid hormone–based medications can stimulate bone formation to treat osteoporosis but are only effective when administered by injection
- Researchers have now identified an oral compound that influences components of the parathyroid hormone signaling pathway to increase bone formation and bone mass in mice
- The investigators are currently working to optimize and develop this compound into a new therapy for patients
Parathyroid hormone can stimulate bone formation, and analogs of the hormone are often prescribed to patients with osteoporosis; however, these medications are only effective when administered by daily injection.
A team led by investigators at Massachusetts General Hospital (MGH) recently identified a promising compound that influences components of the parathyroid hormone signaling pathway and that, when given orally to mice, increases bone mass. The group’s discovery, which is published in PNAS, might lead to a new, more convenient drug for preventing and treating osteoporosis.
“Currently there are no orally available medications for osteoporosis that stimulate bone formation. We sought to develop such medications based upon our detailed understanding of the pathways that normally govern bone production,” says senior author Marc Wein, MD, PhD, an endocrinologist at MGH and an Assistant Professor of Medicine at Harvard Medical School.
The pathway that involves parathyroid hormone inhibits salt-inducible kinase isoforms 2 and 3 (SIK2 and SIK3), which are enzymes with roles in the regulation of bone growth and remodeling.
Wein and his colleagues generated a novel structural model of these enzymes and then used advanced methods including structure-based drug design and iterative medicinal chemistry to identify a compound that potently inhibits SIK2 and SIK3. This compound, termed SK-124, had parathyroid hormone–like effects when given to cells and, most importantly, when fed to mice. In mice, oral treatment once a day for three weeks increased blood levels of calcium and vitamin D and also boosted bone formation and bone mass without evidence of short-term toxicity.
“Based on these findings, we propose that small molecules like SK-124 might represent ‘next generation’ oral bone building therapies for osteoporosis,” says Wein. “We are currently collaborating with a pharmaceutical company—Radius Health, Inc.—to further optimize and develop this compound into a treatment for patients.”
Original Article: New Oral Compound Developed by Mass General Researchers May Help Prevent and Treat Osteoporosis
More from: Massachusetts General Hospital
The Latest Updates from Bing News
Go deeper with Bing News on:
Osteoporosis treatment
- Conditions That Can Go Along With Crohn’s Disease
She says people with Crohn’s disease are at higher risk of having multiple chronic illnesses, including colorectal cancer, osteoporosis ... critical importance of a comprehensive approach to treatment ...
- Graceful Health: Bone density and the silent disease
May is National Women’s Health Month, and I would like to take this opportunity to focus on the importance of Osteoporosis screening for the prevention of fractures. This topic is ...
- Eating 5 or 6 Prunes a Day May Help Preserve Bone Health, Research Shows
A study on postmenopausal women found that daily prune intake could lower inflammatory markers linked to osteoporosis.
- Rheumatism: Taking cortisone with antacids can diminish bone density
Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with ...
- Osteoporosis News
Feb. 21, 2024 — With ever-increasing life expectancy comes the challenge of treating age-related disorders such as osteoporosis. Although there are effective drugs for treating this metabolic ...
Go deeper with Bing News on:
Osteoporosis
- Calcium Hypophosphite - A $311 Million Market by 2030, Driven by Rising Demand for Calcium Supplements and Increasing Prevalence of Osteoporosis
The "Calcium Hypophosphite Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global calcium hypophosphite market is ...
- Graceful Health: Bone density and the silent disease
May is National Women’s Health Month, and I would like to take this opportunity to focus on the importance of Osteoporosis screening for the prevention of fractures. This topic is ...
- Eating 5 or 6 Prunes a Day May Help Preserve Bone Health, Research Shows
A study on postmenopausal women found that daily prune intake could lower inflammatory markers linked to osteoporosis.
- Rheumatism: Taking cortisone with antacids can diminish bone density
Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with ...
- Specific Disease Factors Linked to Osteoporosis Risk in Patients With Systemic Sclerosis
Age, specific disease-related elements, and treatment with glucocorticoids independently affect the risk for osteoporosis among patients with systemic sclerosis. Age, specific disease-related elements ...